Search Results
Mar 04, 2026, 09:05 ET Academy Sports + Outdoors Hits It Out of the Park with Grand Slam Deals on Top Youth Baseball, Softball Brands
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, is excited to announce the return of its
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Mar 03, 2026, 09:05 ET Academy Sports + Outdoors Announces Fourth Quarter and Fiscal 2025 Results Conference Call
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, plans to release its fourth quarter and fiscal 2025 financial results before the
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Mar 03, 2026, 08:41 ET As AI Agents Replace Search Engines, Capxel Introduces AI Search Optimization -- A New Category of Brand Intelligence
majority of brands are invisible to them."Every company has an SEO strategy. Almost none have an ASO strategy," said Dominick Luna, Co-Founder / President of Capxel, who originated the ASO framework. "The brands that show up when an AI agent answers 'What's the best [product] for [use case]?'
More news about: Capxel
Mar 03, 2026, 07:00 ET SpliSense Granted EMA EARLY PRIME Designation for SPL84 in Cystic Fibrosis
ppFEV1 compared with placebo was 10. These data represent the first evidence of potential clinical benefit for an inhaled antisense oligonucleotide (ASO) therapy in a pulmonary disease.About PRIME designationPRIME is granted to medicines that may offer a major therapeutic advantage
More news about: Splisense
Feb 25, 2026, 08:37 ET Capxel Launches LLM-LD, the First Open Standard for Making Websites Readable by AI Agents
AI Search Optimization (ASO) — a discipline conceived by Co-Founder / President Dominick Luna that focuses on structuring brand content for discoverability by AI agents rather
More news about: Capxel
Feb 24, 2026, 16:10 ET Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results
Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements, plus members managed by Complex Care in capitation arrangements and divided by the number of months in the period. Specialty Technology
More news about: Evolent Health, Inc.
Feb 24, 2026, 08:30 ET Therna Biosciences Appoints Biotech Veteran Devyn Smith, Ph.D., to Board of Directors and Expands Strategic and Scientific Advisory Leadership
stability, immune evasion, and tissue-specific expression. The platform also efficiently identifies optimal target sites within mRNA for maximally effective ASO/siRNA design. Therna's technology allows gene expression to be upregulated, downregulated, or finely tuned, enabling broad applications across a range
More news about: Therna Biosciences
Jan 13, 2026, 09:09 ET n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
will co-develop fit-for-purpose access frameworks for n-Lorem's ASO therapies built upon scientific rigor, patient safety, and robust ethical oversight.n-Lorem has led the discovery and development of personalized experimental ASO medicines and currently treats the largest number of nano-rare patients
More news about: EspeRare Foundation
Jan 13, 2026, 03:00 ET n-Lorem und EspeRare kündigen europäische Zusammenarbeit zur Erweiterung des Zugangs zu individualisierten ASO-Therapien für seltene genetische Erkrankungen an
Entwicklung individualisierter und experimenteller ASO-Therapien und behandelt derzeit weltweit die größte Anzahl von Patienten mit seltenen Nano-Erkrankungen. Der industrialisierte Ansatz basiert auf fundierter wissenschaftlicher Expertise, umfassender Expertise in ASO-Technologien und langjähriger Erfahrung in
More news about: EspeRare Foundation
Jan 13, 2026, 03:00 ET n-Lorem and EspeRare annoncent une collaboration européenne pour élargir l'accès aux thérapies ASO individualisées pour les maladies génétiques rares
le développement de traitements ASO individualisés et expérimentaux, et traite aujourd'hui le plus grand nombre de patients nano-rares dans le monde. Son approche industrialisée repose sur une expertise scientifique approfondie, une maîtrise des technologies ASO, ainsi qu'une vaste expérience dans
More news about: EspeRare Foundation
Jan 12, 2026, 13:43 ET n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
will co-develop fit-for-purpose access frameworks for n-Lorem's ASO therapies built upon scientific rigor, patient safety, and robust ethical oversight. n-Lorem has led the discovery and development of personalized experimental ASO medicines and currently treats the largest number of nano-rare
More news about: EspeRare Foundation
Jan 06, 2026, 13:27 ET Aperture Therapeutics Announces First-In-Class MMP9 Antisense Oligonucleotide Program for ALS
precision medicines for neurodegenerative diseases, today announced the advancement of its matrix metalloproteinase-9 (MMP9) antisense oligonucleotide (ASO) program, APRTX-003, for the treatment of Amyotrophic Lateral Sclerosis (ALS). The program targets chronic neuroinflammation and neurodegeneration,
More news about: Aperture Therapeutics
Dec 22, 2025, 05:07 ET AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
proprietary Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining efficient targeted delivery conjugation technologies, the modular Med-Oligo™ platform empowers ASO therapeutics to treat a broad
More news about: AusperBio Therapeutics Inc.
Dec 19, 2025, 09:05 ET Academy Sports + Outdoors Gifts More Than $135,000 to Local Families this Holiday Season
Nasdaq: ASO) is also focused on making a positive impact in local communities. Throughout the holidays, Academy hosted more than 40 giving events, including at
More news about: Academy, Ltd. d/b/a Academy Sports + Outdoors
Dec 17, 2025, 06:50 ET Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
collaboration and option agreement. Under this agreement, the companies have agreed to partner in the discovery of novel antisense oligonucleotide (ASO) therapies against multiple targets for rare renal indications.
More news about: Protalix BioTherapeutics, Inc.; Secarna Pharmaceuticals
Dec 12, 2025, 09:18 ET AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy
proprietary Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining efficient targeted delivery conjugation technologies, the modular Med-Oligo™ Platform empowers ASO therapeutics to treat a broad
More news about: AusperBio Therapeutics Inc.
Dec 12, 2025, 08:35 ET Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy
gene, the largest in the human body, contains 79 exons. Current disease-modifying therapeutic approaches for DMD include antisense oligonucleotides (ASO) mediated exon skipping, gene therapy, and gene editing, with exon skipping being the most common strategy. However, these treatments have significant
More news about: Ractigen Therapeutics
Dec 05, 2025, 09:05 ET Academy Sports + Outdoors Announces Quarterly Cash Dividend
Academy Sports and Outdoors, Inc. (the "Company" or "Academy") (Nasdaq: ASO) announced today that on December 4, 2025, its Board of Directors declared a quarterly cash dividend with respect to the fiscal quarter ended November
More news about: Academy Sports + Outdoors
Dec 02, 2025, 09:05 ET Academy Sports + Outdoors Appoints Three to its Board of Directors
Texas, Dec. 2, 2025 /PRNewswire/ -- Academy Sports and Outdoors, Inc. ("Academy" or the "Company") (Nasdaq: ASO) today announced that Michael Dastugue, Shannon Hennessy, and Clay Johnson have been appointed to its Board of Directors (the "Board"), and Mr. Dastugue
More news about: Academy Sports + Outdoors
Nov 27, 2025, 10:01 ET Orphan Drugs Market to Surge to USD 486.51 Billion by 2032 as Rare Disease Innovation, Gene Therapies & Precision Medicine Reshape Global Healthcare
Commercial scaling of gene therapies for hemoglobinopathies, neuromuscular disorders, and inherited retinal diseasesRise of mRNA & ASO precision medicines targeting ultra-rare genetic variantsDisease-modifying therapies for neurological & metabolic conditionsGlobal
More news about: DataM Intelligence 4 Market Research LLP
Nov 25, 2025, 08:55 ET Academy Sports + Outdoors Announces Third Quarter Fiscal 2025 Results Conference Call
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, plans to release its third quarter fiscal 2025 financial results before the market
More news about: Academy Sports + Outdoors
Nov 20, 2025, 07:00 ET SciNeuro Pharmaceuticals to Accelerate Novel LRRK2 Therapeutic (SNP614) Development with an Award from The Michael J. Fox Foundation
announced it has received a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to advance the company's novel, LRRK2-targeted ASO program (SNP614) toward IND. In tandem, SciNeuro has joined MJFF's LRRK2 Investigative Therapeutics Exchange (LITE) program. This
More news about: SciNeuro Pharmaceuticals
Nov 19, 2025, 10:13 ET Aperture Therapeutics Announces Development Candidate Targeting CD33 to Restore Microglial Homeostasis in FTD and ALS
diseases, today announced the nomination of APRTX-001 as its development candidate. APRTX-001 is a CD33-targeting antisense oligonucleotide (ASO) designed for the treatment of Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS), with strong potential for indication expansion
More news about: Aperture Therapeutics
Nov 18, 2025, 09:05 ET Academy Sports + Outdoors Opens Five New Stores in Q4, Taking New Store Total to 24 in Fiscal 2025
Academy Sports + Outdoors ("Academy" or the "Company") (Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, is excited to announce it has opened five new locations in Q4 2025 in
More news about: Academy Sports + Outdoors
Nov 17, 2025, 11:58 ET EICMA 2025: una edición que bate récords
una buena causa. La exposición se enriqueció aún más con la muestra "Reinas del Desierto", creada en colaboración con ASO – Amaury Sport Organisation: un homenaje a la historia y la leyenda del Rally Dakar, con 31 motocicletas originales expuestas por primera vez en Italia,
More news about: EICMA